source
- RNAi developers see surge in IPOs and funding as industry interest revivesBioPharma Dive’s latest data‑visualization series highlights a rapid rise in interest and investment for companies developing RNA interference (RNAi) medicines. After a years‑long lull, more than…
- BMS reports patient death in MS CAR-T trial, cites septic pneumonia and pauses enrollmentBMS disclosed details about a patient death that occurred in its investigational CAR-T therapy for multiple sclerosis. The autologous CD19-directed CAR-T, zolacabtagene autoleucel (zola-cel), had…